Serum Zinc and Serum Magnesium in Chronic Liver Disease Patients

NCT06827769 | Completed

• 1 other identifier: 36264PR580/2/24
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational cross-sectional study is to assess the relationship between serum levels of magnesium and zinc in pediatric and adult patients with chronic liver disease and the clinic-laboratory variables. Researchers will compare serum levels of zinc and magnesium in patients with chronic liver disease and healthy controls. Assess the correlation between serum zinc and magnesium and the presence and severity of chronic liver disease and cirrhosis. Participants will be subjected to history taking, clinical examination, laboratory investigations, and abdominal ultrasonography.

Conditions

Chronic Liver Disease and Cirrhosis

Keywords

serum zinc,; serum magnesium; chronic liver disease; cirhosis; trace elements

Outcome Measures

Primary Outcomes (2)

• measuring serum zinc level in chronic liver disease patients

  through study completion, an average of 1 year

• measuring serum magnesium level in chronic liver disease patients

  through study completion, an average of 1 year

Secondary Outcomes (1)

• correlation of serum zinc and magnesium with liver disease severity

  through study completion, an average of 1 year

Study Arms (2)

Control

60 healthy subjects as control.

Diagnostic Test: serum zinc and magnesium

Chronic liver disease

80 patients with chronic liver disease diagnosed by physical examination, laboratory investigations, and imaging study. This group will be subdivided into non-cirrhotic and cirrhotic liver groups.

Diagnostic Test: serum zinc and magnesium

Interventions

serum zinc and magnesium DIAGNOSTIC_TEST

participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).

Chronic liver disease; Control

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

subjects from the outpatient clinic and inpatient of the Tropical Medicine and Infectious Diseases Department and Pediatric Department at Tanta University Hospitals

You may qualify if:

• Chronic liver disease diagnosed by physical examination, laboratory investigations, and imaging study.

You may not qualify if:

• Patients with Wilson disease.
• Patients with chronic renal diseases.
• Patients with IBD or any other cause of chronic diarrhea.
• Drugs affecting levels of trace elements e.g. corticosteroids, digoxin thiazide, diuretics, and supplements 30 days before study.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University Hospitals

Tanta, Gharbyea, 31516, Egypt

Location

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Eman B Elsaadany

  Pediatric medicine Department, Faculty of Medicine, Tanta University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Tropical medicine

Study Record Dates

• First Submitted: February 4, 2025
• First Posted: February 14, 2025
• Study Start: March 1, 2024
• Primary Completion: January 30, 2025
• Study Completion: February 1, 2025
• Last Updated: February 14, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)